1. Generics Bulletin
  2. >>Products
  3. >>Biosimilars

Samsung Bioepis Moves Eylea Biosimilar To Phase III

Multiple Phase III Trials For Aflibercept Candidate In Progress

 
• By Dean Rudge

Biosimilar competition to Regeneron’s Eylea (aflibercept) eye-disease biologic may emerge as early as 2023, with at least three firms moving candidates to Phase III development following Samsung Bioepis’ study initiation.

Eye
Samsung now has now pushed two ophthalmic biosimilars into Phase III trials • Source: Shutterstock

Samsung Bioepis has moved its second ophthalmology biosimilar candidate into Phase III trials, with the initiation of comparison studies for its SB15 aflibercept candidate against Regeneron Pharmaceuticals' Eylea (aflibercept) reference brand.

According to an update on the clinicaltrials

Read the full article – start your free trial today!

Join thousands of industry professionals who rely on Generics Bulletin for daily insights

  • Start your 7-day free trial
  • Explore trusted news, analysis, and insights
  • Access comprehensive global coverage
  • Enjoy instant access – no credit card required
Start Free Trial

Already a subscriber?

More from Biosimilars

More from Products